Artya Ltd appoints chief medical officer to further strengthen US expansion

Artrya Ltd (ASX: AYA) has appointed accomplished US physician, senior health care executive and thought leader, Dr. Jacob Agris, MD, PhD, as its new chief medical officer to oversee all medical affairs strategy, clinical development, FDA and global regulatory interactions .

The applied artificial intelligence healthcare company works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk.

Dr Agris’ experience, particularly in analytics and machine learning, will be vital to the company’s aims at coronary heart disease and in being a strategic partner and advisor to the CEO and leadership team.

“Dr. Agris brings a remarkable breadth of knowledge as a practicing physician and recognized leader in data analytics and AI with particular experience leading development of AI for Health Care and navigating regulatory approvals for clinical use,” Artrya managing director and CEO John Barrington AM said.

“There is no doubt he will be a great asset to the company with experience spanning C-suite roles, Fortune 500 companies and as an accomplished physician with a unique blend of computer engineering doctoral studies in data analytics and Machine Learning.

“Together with his track record as an innovator and founding entrepreneur of dynamic start-ups, Dr. Agris is perfectly positioned to lead Artrya’s medical affairs as we grow and evolve as a company,” Barrington said.

Bolstering US presence and experience

The appointment of Dr Agris comes at a time when the medical technology company is hard at work expanding its US footprint.

The new CMO is based in New York and will help the company in its dealings with the FDA.

Artrya has developed deep learning algorithms that will streamline how medical care for heart disease is delivered. Artrya USA Inc. is a wholly-owned subsidiary of Artrya Ltd (ASX: AYA).

Further to the appointment of Dr Agris, former CMO Professor Girish Dwivedi will take on the role of chief scientific officer, leveraging his world-renowned research expertise in coronary plaque.

Leave a Comment

Your email address will not be published.